Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
18 Sep, 2017 (Monday)


CHINARES PHARMA(3320)
Analysis:
CR Pharma is the second largest medicine production and distribution company in China, covering 23 different provinces in China. CR Pharma has a large and strong sales network, distributing medicine to more than 40,000 hospitals and medical institutions and more than 19,000 retail pharmacies. Besides, China has an aging population and increasing life expectancy. According to some research institution, China will have 180 million people with age 65 years or above by 2020. As Chinese citizens have increasing disposable income and increasing coverage of insurance, the future of the healthcare industry is bright.
Strategy:
Buy-in Price: $9.40, Target Price: $11.00, Cut Loss Price: $8.50


BAIC (1958.HK) - 2017H result dropping markedly by 60%, Highlights count on BJ-Benz and NEV

Investment Summary

- 60% Decrease in 2017H Results

- Beijing Mercedes-Benz's doubled profits

- BAIC self-owned brand and Beijing Hyundai all turn gain to loss

Investment Thesis

Judging from the latest sales data, in July, sales volume of Beijing Hyundai and BAIC self-owned brand increased month on month, but we think it is difficult to see a strong rebound in the short term. The strong momentum of Beijing Mercedes-Benz has not diminished, with a sales increase of 48% year on year in July. In terms of new energy vehicles, BAIC self-owned brand, Beijing Hyundai and Beijing Mercedes-Benz have sufficient reserves of new energy models in the low, medium and high fields, aiming to meet the challenges of future new energy market competition.

Semiannual report of the company showed that the result was greatly worse than expected, so we reduced the company's earnings forecast. Earnings per share in 2017/2018 will reach to 0.62/0.84 yuan. We will also reduce target price to 7.62 HKD (10.4/7.7x for 2017/2018 P/E) and rating to careful accumulate.

"One joy" failed to make up for "two worries", with the semi-annual result dropping markedly by 60%

Greatly influenced by its Korean cars sales volume, in the first half of 2017, BAIC net profit decreased dramatically by 59% to RMB986 million, compared to the same period last year. Earnings per share decreased from 0.32 yuan in the same period last year to 0.17 yuan in the first half of 2017.

During the period, the company's total revenue increased by 36% to 66.738 billion yuan year on year, owing to the 56% increase of Beijing Mercedes-Benz's revenue, which partially offset the 28% decrease of BAIC self-owned brand's revenue.

Beijing Mercedes-Benz's doubled profits

In the first half, Beijing Mercedes-Benz continued its explosive growth, with sales volume increasing by 47% to 211,000 units. Beijing Mercedes-Benz recorded an increase of revenue by 56% to 58.3 billion yuan year on year while its gross margin increased by 4% from 28% to 32%, with the contributed net profit from 2.05 billion yuan in the same period last year doubling to 4.24 billion yuan. Based on monthly sales exceeding 10,000 units in the Benz E level, C level and GLC level SUV, three flagship models, medium-term GLA level SUV also got a good sales result in market. In addition, the increase proportion of higher-priced SUV models and new models lead to positive correction in single vehicle revenue and profit: Price of single vehicle is 276,000 yuan, an increase of 6.5% year on year; profit of single vehicle is 39,000 yuan, a big increase of 41% year on year.

BAIC self-owned brand and Beijing Hyundai all turn gain to loss

However, the other two brands, BAIC self-owned brand and Beijing Hyundai suffered dismal results. Restricted by its weak product power, periodic shift and product mix, sales volume of BAIC self-owned brand in the first half deceased by 45.5% to 111,000 units. Revenue related to BAIC self-owned brand decreased by 29% to 8.4 billion yuan, with fractional gross margin decreasing from 2.3% to -15%. Finally it turned from a profit of 400 million yuan to a loss of 3.26 billion yuan in the same period last year.

Influenced by the market competition and political events between China and South Korea, Korean car sales volume continued its sustained downturn this year. In the first half, Beijing Hyundai sales volume decreased by 42.4% year on year, about 300,000 units. Investment income (mainly from Beijing Hyundai) first turned loss, a record low from a profit of 1.98 billion yuan to a loss of 120 million yuan in the same period last year.

Investment Thesis

Judging from the latest sales data, in July, sales volume of Beijing Hyundai and BAIC self-owned brand increased month on month, but we think it is difficult to see a strong rebound in the short term. The strong momentum of Beijing Mercedes-Benz has not diminished, with a sales increase of 48% year on year in July. In terms of new energy vehicles, BAIC self-owned brand, Beijing Hyundai and Beijing Mercedes-Benz have sufficient reserves of new energy models in the low, medium and high fields, aiming to meet the challenges of future new energy market competition.

Semiannual report of the company showed that the result was greatly worse than expected, so we reduce target price to 7.62 HKD (10.4/7.7x P/E) and rating to careful accumulate.

Financials

Click Here for PDF format...




Recommendation on 18-9-2017
RecommendationAccumulate
Price on Recommendation Date$ 6.950
Suggested purchase priceN/A
Target Price$ 7.620
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+ 86 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong 輝立研究部 – 香港及中國
Company Stock Code Last Update Suggestion Target Price Price on Recom
Information Techology Research Department N/A+852 2277 6527research@phillip.com.hk
Karrie International105015/09/2017No Rating1.24
Goldpac Group331527/03/2017Buy32.4
Transportation and Automobiles Zhang Jing (86) 2151699200-103zhangjing@phillip.com.cn
BAIC195818/09/2017Accumulate7.620.000
Dongfeng48911/09/2017Accumulate11.659.9
Insurance Research Department (86) 21 51699400-110research@phillip.com.cn
Media & Publishing Research Department (+ 86 21 51699400-107)research@phillip.com.cn
Wisdom Sports Group166111/07/2016Buy3.32.18
NetDragon77716/06/2016Buy28.422.9
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Tasly Pharmaceutical Group600535.CH24/08/2017Accumulate43.838.52
Hengrui Medicine60027602/08/2017Accumulate 56.551.2
Industrial Goods Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
DONGJIANG ENV89511/08/2017Buy13.810.64
DONGJIANG ENV89515/05/2017Buy14.812.16
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
HEC Pharm155802/06/2017Buy22.2417.08
Luye Pharma218622/03/2017Buy6.34.95
New Energy Wang Yannan 86 21 51699400-107wangyannan@phillip.com.cn
HN RENEWABLES95827/02/2017Buy3.52.72
CONCORD NE18224/10/2016Buy0.60.39
Food, Beverage and Retail Research Department (86) 21 51699400-110research@phillip.com.cn
L`OCCITANE97322/05/2017Accumulate1715.3
L`OCCITANE97319/05/2017Accumulate1715.3
Textiles & Clothing Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
JNBY330613/04/2017Accumulate6.65.95
CECEP COSTIN New Materials Group222818/10/2013Buy5.64.23
Telecommunications Fan Guohe + (86) 21 51699400-110fanguohe@phillip.com.cn
Chinasoft International35409/08/2017Buy5.884.39
Chinasoft International Ltd35410/04/2017Buy5.84.61
Mainland Property John Wong +852 2277 6527johnycwong@phillip.com.hk
KWG Property181314/09/2017Neutral8.48.47
Logan Property338021/08/2017Buy8.87.28
Basic Materials Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
Yip's Chemical40815/06/2017No Rating3.29
ND Paper268905/04/2017Accumulate9.58.35
Utilities Research Department +852 2277 6527research@phillip.com.hk
LK60038813/09/2017Accumulate18.416.13
LK60038812/09/2017Accumulate18.416.13
Properties John Wong +852 2277 6527johnycwong@phillip.com.hk
Swire Properties197230/08/2017Neutral27.327.35
Swire Properties197229/08/2017Neutral27.327.35
Software & Service Research Department (86) 21 51699400-110research@phillip.com.cn
IGG800221/11/2014Accumulate3.953.44
HC INTERNATIONAL228006/11/2014Buy14.928.8
Hotels and Entertainment John Wong (+ 852 2277 6527)johnycwong@phillip.com.hk
Hongkong & Shanghai Hotels4516/08/2017Neutral12.513.18
Hongkong & Shanghai Hotels4515/08/2017Neutral12.513.18

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2017 Phillip Securities (HK) Ltd. All Rights Reserved.